1 / 27

Comparative Efficacy of Antiplatelet Agents: Clopidogrel, Prasugrel, and Ticagrelor in Cardiovascular Events

This document reviews key randomized trials assessing the efficacy of antiplatelet agents, including TRITON-TIMI 38 and PLATO, focusing on their impact on reducing major cardiovascular events. It compares the risk reduction capabilities of Prasugrel and Ticagrelor versus Clopidogrel, analyzes factors associated with switching between first and second-generation ADP receptor inhibitors, and discusses the implications of genetic effects on drug response. Additionally, it highlights the importance of antiplatelet therapy post-PCI and addresses considerations related to inpatient bleeding.

porter-barrera
Télécharger la présentation

Comparative Efficacy of Antiplatelet Agents: Clopidogrel, Prasugrel, and Ticagrelor in Cardiovascular Events

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Introduction

  2. Antiplatelet Agents

  3. ADP Receptor Antagonists

  4. CUREReduction in Cardiovascular Events With Clopidogrel

  5. TRITON-TIMI 38Risk Reduction Prasugrel vs Clopidogrel

  6. PLATOMajor Events: Ticagrelor vs Clopidogrel

  7. Onset of Action

  8. Randomized Trials of Antiplatelet Agents TRITON-TIMI 38 and PLATO

  9. TRANSLATE-ACS

  10. After the Patient Goes Home…

  11. Antiplatelet Use After PCI

  12. Hospitalized Bleeding

  13. TRANSLATE-ACSFactors Associated With In-hospital Switch From 1st- to 2nd-generation ADP Receptor Inhibitor

  14. TRANSLATE-ACSFactors Associated With In-hospital Switch From 2nd to 1st -generation ADP Receptor Inhibitor

  15. Genetic Effects on Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel

  16. TRITON-TIMI 38Risk Reduction: Prasugrel vs Clopidogrel

  17. TRANSLATE-POPS Design

  18. POPS – Change in Treatment

  19. Summary

  20. Abbreviations

  21. Abbreviations (cont)

  22. References

  23. References (cont)

  24. References (cont)

  25. References (cont)

More Related